| Literature DB >> 24369449 |
Matthias J E Arlt1, Ingo J Banke1, Josefine Bertz1, Ram Mohan Ram Kumar1, Roman Muff1, Walter Born1, Bruno Fuchs1.
Abstract
Metastasis is the major cause of death of osteosarcoma patients and its diagnosis remains difficult. In preclinical studies, however, forced expression of reporter genes in osteosarcoma cells has remarkably improved the detection of micrometastases and, consequently, the quality of the studies. We recently showed that Dunn cells equipped with a lacZ reporter gene disseminated from subcutaneous primary tumors as frequently as their highly metastatic subline LM8, but only LM8 cells grew to macrometastases. In the present time-course study, tail-vein-injected Dunn and LM8 cells settled within 24 h at the same frequency in the lung, liver, and kidney of mice. Furthermore, Dunn cells also grew to macrometastases, but, compared to LM8, with a delay of two weeks in lung and one week in liver and kidney tissue, consistent with prolonged survival of the mice. Dunn- and LM8-cell-derived ovary and spine metastases occurred less frequently. In vitro, Dunn cells showed less invasiveness and stronger contact inhibition and intercellular adhesion than LM8 cells and several cancer- and dormancy-related genes were differentially expressed. In conclusion, Dunn cells, compared to LM8, have a similar capability but a longer latency to form macrometastases and provide an interesting new experimental system to study tumor cell dormancy.Entities:
Year: 2013 PMID: 24369449 PMCID: PMC3867932 DOI: 10.1155/2013/404962
Source DB: PubMed Journal: Sarcoma ISSN: 1357-714X
Figure 1Intercellular adhesion, contact inhibition, and invasiveness of Dunn and LM8 cells in vitro. (a) Representative time course of intercellular adhesion and dissociation of Dunn (upper panels) and LM8 (lower panels). Scale bar: 400 μm. (b) Quantification of particle number in percent of the 0 min value. Particle numbers at time zero were 1036 ± 105 and 1313 ± 93 (P > 0.05) in Dunn and LM8, respectively, and were set to 100%. (c) Dissociation by pipetting after 25 h association. Results are the means ± SEM of 3 independent experiments. (d) Intercellular adhesion was further estimated by wounding of confluent cells grown in 24-well plates with a pen and subsequent measurement of the width of the fresh wound as described in Section 2. (e) The cells were grown in 25 cm2 flasks to visual confluence and then trypsinized and counted to estimate differences in contact inhibition. The invasive activity of cells in vitro was determined in a three-dimensional Matrigel degradation and migration assay. Representative microscopic images of LM8 cells seeded in Matrigel drops (500 cells/μL) immediately after gelling (f) and after incubation for 72 h in cell culture medium (g) are shown (scale bars in (f) and (g): 500 μm). Bold arrows in (f) and (g) point to the border of the Matrigel drop, and normal arrows in (g) to foci evading from the Matrigel drop from cell clusters growing inside the Matrigel drop. (h) The number of foci evading from the Matrigel drops (n = 3) was counted daily. (i) The difference between the numbers of Matrigel-evading Dunn and LM8 cell foci per drop (n = 4) peaked at 72 h after cell seeding. All results are shown as the means ± SEM of 3–6 independent experiments. Asterisks (∗) indicate statistically significant difference (P < 0.05).
Number of regulated (>2-fold; P < 0.05) Dunn/LM8 gene sets enriched in KEGG pathways (DAVID).
| Pathways | Gene count | %1 |
|---|---|---|
| Pathways in cancer | 31 | 3.78 |
| Focal adhesion | 22 | 2.68 |
| Cytokine-cytokine receptor interaction | 19 | 2.31 |
| Regulation of actin cytoskeleton | 16 | 1.95 |
| Axon guidance | 14 | 1.71 |
| Cell adhesion molecules (CAMs) | 14 | 1.71 |
| Vascular smooth muscle contraction | 11 | 1.34 |
| ECM-receptor interaction | 10 | 1.22 |
| Apoptosis | 9 | 1.10 |
| Basal cell carcinoma | 8 | 0.97 |
| Complement and coagulation cascades | 8 | 0.97 |
| Adherens junction | 8 | 0.97 |
| Hematopoietic cell lineage | 8 | 0.97 |
| Hedgehog signaling pathway | 7 | 0.85 |
| Glutathione metabolism | 6 | 0.73 |
| Prion diseases | 5 | 0.61 |
| Glycosphingolipid biosynthesis | 4 | 0.49 |
1Proportion of all regulated gene sets.
Genes involved in cancer pathways (KEGG pathway; DAVID) and whose expression is significantly down- or upregulated in LM8 compared to Dunn cells.
| Symbol | Fold change |
| |
|---|---|---|---|
| Genes downregulated in LM8 cells | |||
| Kit ligand | Kitl | −24.57 | 4.26 |
| Peroxisome proliferator activated receptor gamma | Pparg | −15.70 | 2.02 |
| Vascular endothelial growth factor C | Vegfc | −8.20 | 3.50 |
| Prostaglandin-endoperoxide synthase 2 | Ptgs2 | −7.46 | 4.34 |
| Similar to platelet-derived growth factor B chain; platelet-derived growth factor, B polypeptide | Pdgfb | −5.95 | 1.36 |
| Insulin-like growth factor 1 | Igf1 | −4.70 | 3.88 |
| Aryl hydrocarbon receptor nuclear translocator 2 | Arnt2 | −3.80 | 1.16 |
| Endothelial PAS domain protein 1; similar to endothelial PAS domain protein 1 | Epas1 | −3.62 | 1.13 |
| Fibronectin 1 | Fn1 | −2.95 | 5.69 |
| Integrin alpha 3 | Itga3 | −2.79 | 1.02 |
| Integrin alpha 6 | Itga6 | −2.78 | 1.89 |
| Laminin B1 subunit 1 | Lamb1-1 | −2.64 | 8.26 |
| Transforming growth factor, beta 2 | Tgfb2 | −2.43 | 6.09 |
| RAS-related C3 botulinum substrate 3 | Rac3 | −2.37 | 1.65 |
| Bone morphogenetic protein 4 | Bmp4 | −2.26 | 8.64 |
| Signal transducer and activator of transcription 3; similar to Stat3B | Stat3 | −2.23 | 5.64 |
| Transforming growth factor, beta receptor I | Tgfbr1 | −2.15 | 5.06 |
| Fibroblast growth factor receptor 2 | Fgfr2 | −2.14 | 9.69 |
| Interleukin 6 | Il6 | −2.01 | 5.78 |
| Genes upregulated in LM8 cells | |||
| Matrix metallopeptidase 2 | Mmp2 | 6.91 | 4.24 |
| Death-associated protein kinase 2 | Dapk2 | 4.70 | 7.79 |
| Transcription factor 7, T-cell specific | Tcf7 | 3.82 | 1.21 |
| Wingless-related MMTV integration site 1 | Wnt1 | 3.24 | 2.55 |
| Baculoviral IAP repeat-containing 3 | Birc3 | 3.18 | 2.57 |
| Patched homolog 2 | Ptch2 | 3.02 | 1.66 |
| Frizzled homolog 7 ( | Fzd7 | 2.94 | 7.75 |
| Wingless-related MMTV integration site 10a | Wnt10a | 2.64 | 1.93 |
| Fibroblast growth factor 15 | Fgf15 | 2.63 | 2.79 |
| GLI-Kruppel family member GLI2 | Gli2 | 2.59 | 1.62 |
| Similar to wingless-related MMTV integration site 8b; wingless-related MMTV integration site 8b | Wnt8b | 2.39 | 3.89 |
| Predicted gene 10124; predicted gene 6340; CDC28 protein kinase 1b | Cks1b | 2.29 | 1.24 |
Genes with >2 times decrease or increase in expression and a P value < 0.05 were selected and applied to the DAVID program.
Regulation of potential dormancy genes in LM8 compared to Dunn cells.
| Symbol | Fold change |
| |
|---|---|---|---|
| Genes downregulated in LM8 | |||
| Basic helix-loop-helix domain containing, class B9 | Bhlhb9 | −60.98 | 8.46 |
| Fibronectin 1 | Fn1 | −2.95 | 5.69 |
| Transforming growth factor, beta 2 | Tgfb2 | −2.43 | 6.09 |
| Rous sarcoma oncogene | Src | −2.36 | 2.24 |
| Tropomyosin 1, alpha | Tpm1 | −2.28 | 2.53 |
| Transforming growth factor, beta receptor I | Tgfbr1 | −2.15 | 5.06 |
| Genes upregulated in LM8 | |||
| Connective tissue growth factor | Ctgf | 2.72 | 2.18 |
| Genes not differentially regulated in LM8 | |||
| Secreted phosphoprotein 1 | Spp1 | −1.78 | 2.08 |
| A kinase (PRKA) anchor protein (gravin) 12; SSeCKS | Akap12 | −1.67 | 5.18 |
| plasminogen activator, urokinase receptor; uPAR | Plaur | −1.59 | 3.80 |
| Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4); INK4b; p15 | Cdkn2b | −1.47 | 4.66 |
| Discoidin domain receptor family, member 2 | Ddr2 | −1.46 | 2.14 |
| Angiomotin | Amot | −1.16 | 8.07 |
| Thrombospondin 1 | Thbs1 | −1.13 | 1.48 |
| Nuclear receptor subfamily 2, group F, member 2 | Nr2f2 | −1.10 | 2.62 |
| Basic helix-loop-helix family, member e41; Sharp1; Bhlhb3; Bhlhb2l | Bhlhe41 | −1.09 | 2.22 |
| Smad family member 7 | Smad7 | −1.07 | 5.07 |
| NME/NM23 nucleoside diphosphate kinase 1 | Nme1 | −1.03 | 6.95 |
| Insulin-like growth factor binding protein 5 | IGFBP5 | −1.03 | 7.56 |
| Integrin alpha 5 (fibronectin receptor alpha) | Itga5 | −1.02 | 8.71 |
| Mitogen-activated protein kinase kinase 7; MKK7 | Map2k7 | −1.01 | 9.48 |
| Rho, GDP dissociation inhibitor (GDI) beta; RhoGD12 | Arhgdib | −1.01 | 9.05 |
| Mitogen-activated protein kinase 14; p38 | Mapk14 | −1.01 | 8.66 |
| Eph receptor A5 | EphA5 | −1.01 | 9.06 |
| Integrin beta 1 (fibronectin receptor beta) | Itgb1 | 1.01 | 9.52 |
| Transformation related protein 53; p53 | Trp53 | 1.02 | 7.07 |
| Endothelial cell-specific molecule 1 | Esm1 | 1.03 | 6.89 |
| Mitogen-activated protein kinase kinase 4; MKK4 | Map2k4 | 1.04 | 7.06 |
| Tissue inhibitor of metalloproteinases 3 | Timp3 | 1.04 | 6.82 |
| Eph receptor B2; Erk | Ephb2 | 1.05 | 7.47 |
| CD82 antigen; Kai1 | Cd82 | 1.06 | 4.01 |
| Mitogen-activated protein kinase kinase 6; MKK6 | Map2k6 | 1.07 | 3.79 |
| 5′ Nucleotidase, ecto; CD73 | Nt5e | 1.08 | 4.20 |
| Epidermal growth factor receptor | Egfr | 1.11 | 3.53 |
| Phosphatidylinositol 3-kinase, catalytic, beta polypeptide | PI3K (Pik3cb) | 1.12 | 3.09 |
| Twist basic helix-loop-helix transcription factor 2 | Twist2 | 1.13 | 1.30 |
| Mediator complex subunit 23; CRSP3 | Med23 | 1.15 | 7.53 |
| Lysophosphatidic acid receptor 1; Edg2 | Lpar1 | 1.19 | 1.46 |
| Breast cancer metastasis-suppressor 1-like | Brms1l | 1.27 | 2.76 |
| GATA binding protein 3 | Gata3 | 1.34 | 1.45 |
| Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide | P4ha1 | 1.75 | 4.28 |
Genes with >2 times decrease or increase in expression and a P value < 0.05 were considered as significantly regulated. For Igf1r, Kiss1, and Hist1h2bk no data were available on the microarray.
Figure 2(a) qRT-PCR analysis of Mmp2, Bhlhb9, Fn1, and Src mRNA expression normalized to Gapdh in Dunn and LM8 cells. For comparison the fold-change values calculated from the microarray data are indicated above the graph. (b) Representative western blots of MMP2 protein levels in FCS-free supernatant of Dunn and LM8 cells and (c) quantitative analysis of three independent western blots experiments. Results are shown as the means ± SEM.
Figure 3Appearance over time of experimental metastases in indicated organs after intravenous injection of lacZ-transduced Dunn and LM8 cells in C3H mice. ((a)–(c)) Images show X-gal-stained metastases in blue in representative whole mounts and ((a), (b)) corresponding close-ups of lungs (a), livers (b), and kidneys (c) collected from mice that were sacrificed at indicated time points after tumor cell injection. (d) Schematic summary of the first appearance of micro- and macrometastases (>0.1 mm) over time in indicated organs.
Figure 4Animal survival and tissue distribution of metastases at sacrifice in mice intravenously injected with lacZ-transduced Dunn or LM8 OS cells. (a) Kaplan-Meier survival curves of C3H mice injected with LM8 (red line) or Dunn (blue line) cells. (b) Metastatic pattern in lung (i-ii), liver (iii-iv), urogenital tract (v-vi), and spine (vii-viii) of moribund mice at sacrifice.